Fenwick represented The Arena Group on the deal. The Arena Group (NYSE American: AREN), a tech-powered media company home to more than 240 brands, including Sports...
The Arena Group’s Acquisition of Digital Assets from a360Media
Idera Pharmaceuticals’ Acquisition of Aceragen
Fenwick represented Aceragen on the deal, Morgan Lewis advised Idera Pharmaceuticals. Aceragen, a privately-held biotechnology company addressing rare, orphan pulmonary and rheumatic diseases for which there...
Third Harmonic Bio’s $213.1 Million IPO
Fenwick represented Third Harmonic Bio, Inc. on the deal. Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT...
Castlight Health’s $370 Million Combination with Vera Whole Health
Fenwick & West advised Castlight Health on the deal, while Kirkland & Ellis advised Vera Whole Health. Castlight Health (NYSE: CSLT), a leading healthcare data and...
DICE Therapeutics’ $204 Million Initial Public Offering
Fenwick & West advised DICE Therapeutics on the deal. DICE Therapeutics (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of...
Leeward Renewable Energy Operations’ $375 Million Green Bond Offering
Shearman & Sterling advised Leeward Renewable Energy Operations, while Latham & Watkins represented the initial purchasers in the offering. Leeward Renewable Energy Operations, a wholly owned...